Brolucizumab shows noninferiority to aflibercept for treatment of AMD

MIAMI — Two phase 2 studies comparing brolucizumab vs. aflibercept for the treatment of neovascular age-related macular degeneration showed comparable efficacy results at 40 weeks of follow-up, according to a speaker here.“There are two phase 2 studies, and their endpoints shows noninferiority to aflibercept and ranibizumab, justifying progression to a phase 3 study of brolucizumab. Brolucizumab has the potential to address a significant unmet clinical need in the treatment of neovascular AMD by reducing treatment burden,” Lawrence J. Singerman, MD, FACS, said at Angiogenesis, Exudation, and Degeneration 2017.

Full Story →